Jason Harris

This inventor holds 12 USPTO granted patents and 12 published patent applications, plus 5 CIPO patents and 5 EPO patents. Top assignees: Escalier Biosciences B.v., Zomagen Biosciences Ltd, Oppilan Pharma Ltd.. Active years: 2020-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jason Harris. Retrieved from https://idiyas.com/inventor/jason-harris-kzgkc9yp

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 12 (Patent Applications = 12)

% Patents Active = 91.7

CIPO Patents = 5 (Patent Applications = 3)

EPO Patents = 5 (Patent Applications = 13)

Average Co-Inventor Count = 3.8

ph-index = 1

Forward Citations = 5(Granted Patents)

Location History:

Carlsbad, CA (US) (2020 - 2021)
Encinitas, CA (US) (2021 - 2023)

Company Filing History:

3 out of 3

Escalier Biosciences B.v.

patents

3 out of 3

Zomagen Biosciences Ltd

Ventyx Biosciences, Inc.

patents

5. 2 out of 2

Vimalan Biosciences, Inc.

patents

Years Active: 2020-2026

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12612401 - Crystalline forms of an S1P receptor modulator (2026-04-28),

2. 12466800 - N-((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)-4, 5, 6, 7-tetrahydrobenzofuran-2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (MS) (2025-11-11),

3. 12351564 - NLRP3 modulators (2025-07-08),

4. 11780842 - TYK2 pseudokinase ligands (2023-10-10),

5. 11753411 - Substituted pyrazolo[1,5-a]pyrimidines as TYK2 pseudokinase ligands (2023-09-12),

6. 11603375 - NLRP3 modulators (2023-03-14),

7. 11459333 - Substituted pyrrolo[2,3-d]pyrimidines as JAK inhibitors (2022-10-04),

8. 11242350 - Spirocyclic ROR-gamma modulators (2022-02-08),

9. 11230555 - Bicyclic RORγ modulators (2022-01-25),

10. 11136329 - JAK inhibitors (2021-10-05),

11. 10905687 - Substituted piperazines as ROR-gamma modulators (2021-02-02),

12. 10683291 - Heterocyclic compounds for the treatment of disease (2020-06-16),

Title: Jason Harris: Innovator in Pharmaceutical Modulation

Introduction

Jason Harris is a prominent inventor based in Encinitas, California. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of modulators for various diseases and disorders. With a total of 10 patents to his name, Harris has established himself as a key figure in innovation.

Latest Patents

Among his latest patents are the NLRP3 modulators, which are described as compounds that can be utilized in the treatment of various diseases, disorders, or conditions. These modulators include pharmaceutically acceptable salts or solvates and are accompanied by pharmaceutical compositions that enhance their efficacy. Another notable patent involves TYK2 pseudokinase ligands, which also focus on treating diseases and disorders. These ligands are supported by pharmaceutical compositions that facilitate their application in medical treatments.

Career Highlights

Throughout his career, Jason Harris has worked with several notable companies, including Escalier Biosciences and Vimalan Biosciences, Inc. His work in these organizations has allowed him to further his research and development efforts in the pharmaceutical industry.

Collaborations

Harris has collaborated with esteemed colleagues such as Raju Mohan and John M Nuss. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Jason Harris is a distinguished inventor whose work in pharmaceutical modulation has the potential to impact the treatment of various diseases. His innovative patents and collaborations highlight his commitment to advancing medical science.

Profile summary based on public USPTO records.